Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS)

Immunobiology

Volumn 221, Issue 6, 2016, Pages 715-718

  Wong, Edwin ^a   Challis, Rachel ^a   Sheerin, Neil ^b   Johnson, Sally ^b   Kavanagh, David ^a   Goodship, Timothy H J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

AHUS; Complement; Genetics; Treatment

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; COMPLEMENT INHIBITOR; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; THROMBOMODULIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ARTICLE; COHORT ANALYSIS; COMPLEMENT ACTIVATION; COMPLEMENT DISORDER; DISEASE PREDISPOSITION; DRUG APPROVAL; DRUG EFFICACY; ENGLAND; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENETIC ANALYSIS; HEALTH CARE FINANCING; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HEREDITY; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MEDICAL EXPERT; NATIONAL HEALTH SERVICE; OPEN STUDY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; RENAL REPLACEMENT THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); COMPLEMENT ALTERNATIVE PATHWAY; GENETICS; GRAFT RECIPIENT; PHYSIOLOGIC MONITORING; RISK;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; ENGLAND; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MONITORING, PHYSIOLOGIC; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK; TRANSPLANT RECIPIENTS;

EID: 84973267298     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.05.002     Document Type: Article

References (27)

1. Ardissino G., Testa S., Possenti I., Tel F., Paglialonga F., Salardi S., Tedeschi S., Belingheri M., Cugno M. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am. J. Kidney Dis. 2014, 64:633.
2. Bresin E., Daina E., Noris M., Castelletti F., Stefanov R., Hill P., Goodship T.H.J., Remuzzi G. Outcome of renal transplantation in patients with non-shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin. J. Am. Soc. Nephrol. 2006, 1:88.
3. Bresin E., Rurali E., Caprioli J., Sanchez-Corral P., Fremeaux-Bacchi V., Rodriguez de Cordoba S., Pinto S., Goodship T.H., Alberti M., Ribes D., Valoti E., Remuzzi G., Noris M., European Working Party on Complement Genetics in Renal Diseases Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J. Am. Soc. Nephrol. 2013, 24:475.
4. Bruneau S., Neel M., Roumenina L.T., Frimat M., Laurent L., Fremeaux-Bacchi V., Fakhouri F. Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation. Blood 2015, 125:1038.
5. Esparza-Gordillo J., Goicoechea de J.E., Buil A., Carreras B.L., Lopez-Trascasa M., Sanchez-Corral P., Rodriguez de C.S. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum. Mol. Genet. 2005, 14:703.
6. Fakhouri F., Roumenina L., Provot F., Sallee M., Caillard S., Couzi L., Essig M., Ribes D., Dragon-Durey M.A., Bridoux F., Rondeau E., Fremeaux-Bacchi V. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J. Am. Soc. Nephrol. 2010, 21:859.
7. Gasser C., Gautier E., Steck A., Oechslin R. Haemolytisch-uraemische syndrome: bilaterale nierenrindennekrosen bie akuten erworbenen hamoltischen anamien. Sonderabdruck aus der Schweizerischen Medizinischen Wochenschrift 1955, 85:905.
8. Gruppo R.A., Rother R.P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 360:544.
9. Hillmen P., Muus P., Roth A., Elebute M.O., Risitano A.M., Schrezenmeier H., Szer J., Browne P., Maciejewski J.P., Schubert J., Urbano-Ispizua A., de Castro C., Socie G., Brodsky R.A. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 2013, 162:62.
10. Kaplan B.S., Chesney R.W., Drummond K.N. Hemolytic uremic syndrome in families. N. Engl. J. Med. 1975, 292:1090.
11. Kavanagh D., Pappworth I.Y., Anderson H., Hayes C.M., Moore I., Hunze E.M., Bennaceur K., Roversi P., Lea S., Strain L., Ward R., Plant N., Nailescu C., Goodship T.H., Marchbank K.J. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?. Clin. J. Am. Soc. Nephrol. 2012, 7:417.
12. Kavanagh D., Goodship T.H., Richards A. Atypical hemolytic uremic syndrome. Semin. Nephrol. 2013, 33:508.
13. Kelly R.J., Hill A., Arnold L.M., Brooksbank G.L., Richards S.J., Cullen M., Mitchell L.D., Cohen D.R., Gregory W.M., Hillmen P. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011, 117:6786.
14. Le Quintrec M., Zuber J., Moulin B., Kamar N., Jablonski M., Lionet A., Chatelet V., Mousson C., Mourad G., Bridoux F., Cassuto E., Loirat C., Rondeau E., Delahousse M., Fremeaux-Bacchi V. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am. J. Transplant. 2013, 13:663.
15. Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C., Bingham C., Cohen D.J., Delmas Y., Douglas K., Eitner F., Feldkamp T., Fouque D., Furman R.R., Gaber O., Herthelius M., Hourmant M., Karpman D., Lebranchu Y., Mariat C., Menne J., Moulin B., Nurnberger J., Ogawa M., Remuzzi G., Richard T., Sberro-Soussan R., Severino B., Sheerin N.S., Trivelli A., Zimmerhackl L.B., Goodship T., Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2013, 368:2169.
16. Lemaire M., Fremeaux-Bacchi V., Schaefer F., Choi M., Tang W.H., Le Quintrec M., Fakhouri F., Taque S., Nobili F., Martinez F., Ji W., Overton J.D., Mane S.M., Nurnberg G., Altmuller J., Thiele H., Morin D., Deschenes G., Baudouin V., Llanas B., Collard L., Majid M.A., Simkova E., Nurnberg P., Rioux-Leclerc N., Moeckel G.W., Gubler M.C., Hwa J., Loirat C., Lifton R.P. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat. Genet. 2013, 45:531.
17. Licht C., Greenbaum L.A., Muus P., Babu S., Bedrosian C.L., Cohen D.J., Delmas Y., Douglas K., Furman R.R., Gaber O.A., Goodship T., Herthelius M., Hourmant M., Legendre C.M., Remuzzi G., Sheerin N., Trivelli A., Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015, 87(5):1061-1073.
18. Moore I., Strain L., Pappworth I., Kavanagh D., Barlow P.N., Herbert A.P., Schmidt C.Q., Staniforth S.J., Holmes L.V., Ward R., Morgan L., Goodship T.H.J., Marchbank K.J. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4 and with mutations in CFH, CFI, CD46, and C3 in patients with atypical haemolytic uraemic syndrome. Blood 2010, 115:379.
19. Nishimura J., Yamamoto M., Hayashi S., Ohyashiki K., Ando K., Brodsky A.L., Noji H., Kitamura K., Eto T., Takahashi T., Masuko M., Matsumoto T., Wano Y., Shichishima T., Shibayama H., Hase M., Li L., Johnson K., Lazarowski A., Tamburini P., Inazawa J., Kinoshita T., Kanakura Y. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med. 2014, 370:632.
20. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., Daina E., Fenili C., Castelletti F., Sorosina A., Piras R., Donadelli R., Maranta R., van der Meer I., Conway E.M., Zipfel P.F., Goodship T.H., Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 2010, 5:1844.
21. Noris M., Galbusera M., Gastoldi S., Macor P., Banterla F., Bresin E., Tripodo C., Bettoni S., Donadelli R., Valoti E., Tedesco F., Amore A., Coppo R., Ruggenenti P., Gotti E., Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014, 124:1715.
22. Peffault de Latour R., Fremeaux-Bacchi V., Porcher R., Xhaard A., Rosain J., Castaneda D.C., Vieira-Martins P., Roncelin S., Rodriguez-Otero P., Plessier A., Sicre de Fontbrune F., Abbes S., Robin M., Socie G. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015, 125:775.
23. Sanchez Chinchilla D., Pinto S., Hoppe B., Adragna M., Lopez L., Justa Roldan M.L., Pena A., Lopez Trascasa M., Sanchez-Corral P., Rodriguez de Cordoba S. Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 2014, 9:1611.
24. Sheerin N.S., Kavanagh D., Goodship T.H., Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. Q. J. Med. 2015, 10.1093/qjmed/hcv082.
25. Valoti E., Alberti M., Tortajada A., Garcia-Fernandez J., Gastoldi S., Besso L., Bresin E., Remuzzi G., Rodriguez de Cordoba S., Noris M. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J. Am. Soc. Nephrol. 2015, 26:209.
26. Venables J.P., Strain L., Routledge D., Bourn D., Powell H.M., Warwicker P., Diaz-Torres M.L., Sampson A., Mead P., Webb M., Pirson Y., Jackson M.S., Hughes A., Wood K.M., Goodship J.A., Goodship T.H. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med. 2006, 3:e431.
27. Warwicker P., Goodship T.H.J., Donne R.L., Pirson Y., Nicholls A., Ward R.M., Goodship J.A. Genetic studies into inherited and sporadic haemolytic uraemic syndrome. Kidney Int. 1998, 53:836.